Professor Hazel Squires
BSc (ºù«Ӱҵ), MSc (Lancaster), PhD (ºù«Ӱҵ)
Population Health, School of Medicine and Population Health
Professor of Health-Related Decision Modelling
+44 114 222 0765
Full contact details
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
ºù«Ӱҵ
S1 4DA
- Profile
-
I joined ScHARR in 2005 after completing a BSc in Mathematics from the University of ºù«Ӱҵ and an MSc in Operational Research from Lancaster University. Since joining ScHARR, I have undertaken modelling projects for NICE, the Department of Health, the NHS Cancer Screening Programme and the pharmaceutical industry. A large part of this work has been around Public Health interventions and cancer screening, diagnosis and treatment. In 2010 - 2013 I developed a framework for helping modellers develop the structure of Public Health economic models as part of a NIHR doctoral research fellowship.
I am currently undertaking a NIHR Advanced Fellowship, exploring methods for incorporating behaviour into health economic models of Public Health interventions.
I contribute to PhD and Masters programmes in ScHARR including being one of the supervisors of the Wellcome Doctoral Training Centre in and part of the module team Advanced Simulation Methods.
- Research interests
-
- Healthcare economic modelling
- Modelling within public health
- Conceptual modelling
- Individual-level simulation to model healthcare systems
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . BMC Public Health, 24(1).
- . Emergency Medicine Journal, 41(1).
- . Value in Health, 26(12), 1738-1743.
- . Health Economics.
- . Public Health, 194, 263-269.
- . BMC Public Health, 21.
- . Health technology assessment, 21(68).
- . Diabetic Medicine, 34(5), 632-640.
- . Value in Health, 19(5), 588-601.
- . PharmacoEconomics, 34(7), 673-680.
- . International Journal of Public Health, 61(3), 289-298.
- . Appl Health Econ Health Policy, 12(3), 239-253.
- . International Journal of Systems Science, 45(1), 60-68.
- . J Public Health (Oxf), 34(1), 115-124.
- . Health Technol Assess, 15(40), 1-210.
- . Clinical Therapeutics, 33(9), 1289-1305.
- . J OPER RES SOC, 60(10), 1305-1314.
- Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(10).
- . J OPER RES SOC, 59(7), 902-910.
- . Health Economics.
All publications
Journal articles
- . BMC Public Health, 24(1).
- . Nicotine and Tobacco Research, ntae225.
- . BMC Public Health, 24(1).
- . Emergency Medicine Journal, 41(1).
- . Value in Health, 26(12), 1738-1743.
- . Health Economics.
- . BMC Geriatrics, 23(1).
- . Cost Effectiveness and Resource Allocation, 20(1).
- . BMC Health Services Research, 22(1).
- . BMC Health Services Research, 22(1).
- . BMC Health Services Research, 21(1).
- . Public Health, 194, 263-269.
- . BMC Public Health, 21.
- . British Journal of Ophthalmology.
- . British Journal of Ophthalmology.
- . PharmacoEconomics.
- . PharmacoEconomics, 36(1), 29-38.
- . Health technology assessment, 21(68).
- . Journal of Epidemiology and Community Health, 71, 897-904.
- . BMJ Open, 7.
- . Diabetic Medicine, 34(8), 1136-1144.
- . Diabetic Medicine, 34(5), 632-640.
- . J Public Health (Oxf), 38(4), 679-687.
- . Value in Health, 19(5), 588-601.
- . PharmacoEconomics, 34(7), 673-680.
- . International Journal of Public Health, 61(3), 289-298.
- . Diabetic Medicine, 33(8), 1155-1163.
- . Appl Health Econ Health Policy, 12(3), 239-253.
- . Angiology, 65(3), 190-197.
- . International Journal of Systems Science, 45(1), 60-68.
- . Br J Surg, 100(13), 1838-1839.
- . Value in Health.
- . Value Health, 15(8), 1127-1136.
- . The Lancet, 380, S68-S68.
- . British Journal of Surgery, 99(12), 1630-1638.
- . PLoS ONE, 7(2).
- . J Public Health (Oxf), 34(1), 115-124.
- . Health Technol Assess, 15(40), 1-210.
- . Clinical Therapeutics, 33(9), 1289-1305.
- . J Fam Plann Reprod Health Care, 37(2), 71-84.
- . Eur J Contracept Reprod Health Care, 16(3), 149-160.
- . Value in Health, 14(5), 768-776.
- . Colorectal Dis, 13(10), 1085-1099.
- . Int J Technol Assess Health Care, 26(4), 362-369.
- . Health Technol Assess, 14(32), 1-206.
- . J Pediatr Adolesc Gynecol, 23(6), 341-351.
- . CLIN THER, 32(5), 789-803.
- . Aliment Pharmacol Ther, 31(7), 708-718.
- . International Journal of Technology Assessment in Health Care, 26(4), 362-369.
- . Disabil Rehabil, 32(8), 607-621.
- . Journal of Pediatric and Adolescent Gynecology.
- . J OPER RES SOC, 60(10), 1305-1314.
- . Int J Technol Assess Health Care, 25(4), 470-478.
- . Health Technol Assess, 13 Suppl 1, 1-6.
- . Health Technol Assess, 13(10), iii-103.
- Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(10).
- Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(10).
- . J OPER RES SOC, 59(7), 902-910.
- . BJOG-INT J OBSTET GY, 115(6), 749-757.
- . Blood, 110(11), 5175-5175.
- Questions about adjuvant trastuzamab still remain (vol 369, pg 3, 2007). LANCET, 369(9562), 642-642.
- . Lancet, 369(9555), 3-5.
- . BMC Geriatrics, 24(1).
- . Health Economics.
- . Wellcome Open Research, 7, 7-7.
- . Wellcome Open Research, 7, 7-7.
- . Health Technology Assessment, 13(Suppl 1), 1-6.
- What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation. BMJ Open.
Conference proceedings papers
- . Value in Health, Vol. 17(7) (pp A556-A556)
- . Value in Health, Vol. 17(7) (pp A347-A347)
- . VALUE IN HEALTH, Vol. 15(7) (pp A633-A633)
- COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSES IMATINIB FOR THE TREATMENT OF CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKAEMIA. HAEMATOLOGICA, Vol. 97 (pp 314-314)
- . VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
- . VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
- A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 141 (pp 38-38)
- A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib.. BLOOD, Vol. 110(11) (pp 376B-376B)
- Incorporating the COM-B model for behavior change into an agent-based model of smoking behaviors: an object-oriented design. Proceedings of the 2024 Winter Simulation Conference. Orlando, Florida, 15 December 2024 - 15 December 2024.
Posters
- Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer.
Datasets
Other
Preprints
- Teaching interests
-
- Mathematical modelling within healthcare
- Discrete event simulation
- Healthcare economic modelling
- Professional activities and memberships
-
- Editorial Board of Journal of Simulation
- I am a member of the Operational Research Society.